Trusted Resource for Clinical Trials, Protocols & Progress
EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) is the centralized platform for registering interventional clinical trials conducted within the European Economic Area (EEA). Managed by the European Medicines Agency (EMA), this registry ensures transparency, ethical oversight, and compliance with the EU Clinical Trials Directive (2001/20/EC) and Clinical Trials Regulation (EU) No 536/2014.
Click to read the full article.
With globalization of clinical trials, it’s common for sponsors to run multi-country studies that span both the United States and the European Union. This dual footprint necessitates registration in both ClinicalTrials.gov (administered by the U.S. National Library of Medicine) and EudraCT (administered by the European Medicines Agency). Each registry has its own process, data fields, compliance timelines, and posting obligations.
Click to read the full article.
With the evolution of transparency regulations across the European Union, sponsors conducting clinical trials in EU Member States must comply with EudraCT posting requirements. EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) was developed to facilitate ethical review coordination and provide public visibility into trial activities across Europe. The obligations placed on sponsors are not just administrative — they are legally binding, enforceable under Regulation (EU) No 536/2014, and evaluated during GCP inspections.
Click to read the full article.
The European Clinical Trials Regulation (EU) No 536/2014 (CTR) was enacted to address the inefficiencies and inconsistencies that plagued the prior EU clinical trial framework under Directive 2001/20/EC. With its full implementation via the Clinical Trials Information System (CTIS), CTR replaces EudraCT for all new clinical trials starting January 31, 2023. However, EudraCT remains relevant for legacy studies initiated before this date, creating a dual landscape of regulatory obligations. This article explains how sponsors can navigate the regulatory overlap, implement compliance strategies, and prepare for inspections under CTR and EudraCT.
Click to read the full article.
Timely registration and results posting on EudraCT are mandatory for sponsors conducting clinical trials in the European Union. These requirements support ethical transparency, regulatory oversight, and public access to trial information. Non-compliance can lead to enforcement actions, public disclosure failures, or rejection during inspections. This tutorial provides a comprehensive understanding of the critical EudraCT-related timelines and their implications, especially as the transition to the Clinical Trials Regulation (CTR) continues.
Click to read the full article.
Amendments are a critical part of the clinical trial lifecycle, allowing sponsors to update protocols, investigator brochures (IBs), informed consent forms (ICFs), and trial-specific procedures. In the European Union, such changes must be reported to competent authorities via EudraCT depending on their classification. Proper handling ensures continued regulatory compliance and ethical oversight. This tutorial provides a comprehensive guide to submitting amendments in EudraCT and meeting EMA expectations.
Click to read the full article.
EudraCT (European Union Drug Regulating Authorities Clinical Trials) is a centralized database established to fulfill transparency and accountability requirements for interventional clinical trials in the EU. Regulatory authorities, including the European Medicines Agency (EMA), rely on EudraCT to evaluate sponsor compliance, track study progress, and ensure that the rights and safety of trial participants are upheld. As the EU transitions toward CTIS under Regulation (EU) No 536/2014, the legacy responsibilities of EudraCT remain enforceable for trials initiated before January 31, 2023.
Click to read the full article.
While the EudraCT system was originally built with commercial sponsors in mind, academic and non-commercial trials are equally subject to European Union transparency obligations. Any interventional clinical trial involving human participants and authorized under Directive 2001/20/EC must be registered in EudraCT. This includes trials sponsored by universities, hospitals, research institutes, and investigator-led academic networks.
Click to read the full article.
Clinical trial audits in the European Union increasingly include checks on EudraCT registry compliance. The EudraCT database is not just a transparency platform but a regulatory record under EU law. Sponsors—whether academic, non-commercial, or industry—are responsible for timely trial registration, accurate updates, and submission of summary results. Any deviation in these responsibilities can lead to audit observations, delayed approvals, or reputational harm.
Click to read the full article.
As clinical trial inspections increasingly include scrutiny of public registry compliance, proper archiving of EudraCT documents becomes essential. Regulatory authorities such as EMA, BfArM, and national GCP inspectorates require sponsors to retain proof of EudraCT compliance—including registration confirmation, trial updates, and summary result uploads. Failing to present these documents during an audit may result in findings under EU GCP and data transparency regulations.
Click to read the full article.
